Polypharmacy in Long-Term Care: What It Is, Why It Matters, and How Good Pharmacy Management Addresses It
Polypharmacy — the concurrent use of multiple medications — is one of the most pervasive and clinically significant challenges in long-term care. The average resident in a skilled nursing or assisted living facility takes eight to ten medications daily, a number that often reflects years of accumulated prescriptions from multiple providers across multiple care settings.
That accumulation is rarely anyone’s fault. Each medication, at the time it was prescribed, addressed a real clinical need. The problem is that medication regimens don’t self-correct. Without regular, systematic review, they tend to grow rather than shrink — and the risks compound accordingly.
What polypharmacy actually looks like
Polypharmacy is broadly defined as five or more concurrent medications, though in LTC settings, ten or more is common. The challenge isn’t volume alone — it’s what happens when medications that made sense individually begin to interact in ways no single prescriber anticipated.
Consider a resident managing heart failure, type 2 diabetes, chronic pain, depression, and early-stage dementia. Each condition likely has one or more medications associated with it. Add PRN medications for anxiety or sleep, a supplement regimen, and the occasional antibiotic course, and the list grows quickly. Each prescriber knows their portion of the picture. No single person knows the whole picture — unless a clinical pharmacist is actively reviewing it.
The clinical risks that follow
Falls
Fall risk is one of the most direct consequences of unmanaged polypharmacy in elderly residents. Benzodiazepines, sleep medications, certain antidepressants, and drugs with anticholinergic properties all increase fall risk — sometimes individually, and often additively when combined. The American Geriatrics Society’s Beers Criteria identifies dozens of medications as potentially inappropriate for older adults, many specifically because of their fall-related risk profile. Falls remain one of the most frequently cited deficiencies in CMS surveys and one of the leading causes of serious injury in LTC settings.
Cognitive decline that isn’t dementia
Anticholinergic medications — a category that includes certain bladder medications, antihistamines, and some antidepressants — carry meaningful cognitive side effects in older adults. Symptoms like confusion, agitation, and memory decline can be nearly indistinguishable from dementia progression. When a resident’s cognitive status changes, the question worth asking before assuming disease progression is: has anything changed in their medication regimen?
Drug-drug interactions
The probability of a clinically significant drug-drug interaction increases substantially as the number of concurrent medications grows. Some interactions are well-known; others are subtler, producing symptoms — fatigue, appetite loss, mood changes — that get attributed to aging or illness rather than traced to their pharmaceutical cause. Systematic pharmacist review is the primary mechanism for catching these before they result in a clinical event.
What the regulations require
CMS recognizes polypharmacy as a patient safety issue and has built medication management requirements directly into the federal survey process.
F756 requires that each SNF resident receive a monthly drug regimen review by a licensed pharmacist. The review must identify irregularities — unnecessary medications, potentially harmful combinations, doses that may be inappropriate given the resident’s current condition — and report findings to the prescriber and the Director of Nursing.
F758 specifically addresses unnecessary medications, with particular attention to psychotropic drugs and antipsychotics. For antipsychotics, gradual dose reduction (GDR) trials are required unless clinically contraindicated — a requirement that is actively surveyed and among the more commonly cited medication-related deficiencies in skilled nursing surveys.
These aren’t documentation requirements in name only. They represent a federally enforced baseline for what clinical pharmacy oversight in LTC should look like.
What good pharmacy management actually does
The gap between a pharmacy that completes a monthly medication review and one that conducts a substantive clinical review shows up over time — in survey outcomes, in hospitalization rates, and in the daily burden placed on your nursing staff.
Substantive monthly medication regimen reviews generate real recommendations: dose changes, deprescribing candidates, formulary alternatives that reduce interaction risk. If the pharmacist’s monthly reports are generic, or if recommendations are routinely not communicated or acted on, the review is fulfilling a compliance requirement rather than a clinical one.
The other differentiator is proactive communication. A pharmacy partner that actively monitors residents’ medication regimens — rather than waiting to be called — is in a qualitatively different category. When a new admission arrives with a complex medication list, when a resident’s lab values suggest a dose needs adjustment, when a potential interaction surfaces: those conversations should be initiated by the pharmacy, not the nursing team.
A note on deprescribing
Deprescribing — the systematic tapering or discontinuation of medications that are no longer necessary or whose risks outweigh their benefits — is increasingly recognized as an essential component of geriatric care. It’s not about reducing medications for cost reasons; it’s about regularly asking whether each medication in a resident’s regimen is still doing what it was prescribed to do, at the dose it was prescribed.
For LTC facilities, deprescribing conversations require close coordination between the prescriber, the nursing team, and the pharmacist. A pharmacy partner with genuine clinical depth can facilitate those conversations — identifying candidates, documenting the clinical rationale, and monitoring for changes after dose reductions.
How this plays out across care settings
Polypharmacy management looks different depending on where a resident is in the care continuum. In skilled nursing facilities, the regulatory framework is clearly defined — monthly reviews are required, and survey exposure is real. In assisted living and independent living settings, the regulatory floor is lower, but the clinical risks are the same. In memory care settings, where residents often carry complex psychotropic regimens and where behavioral changes can mask medication side effects, the stakes are particularly high.
In each of these settings, the quality of pharmacy oversight makes a material difference in clinical outcomes — and in the workload placed on nursing staff every shift.
If you have questions about how Friendship Pharmacy approaches medication regimen review, or want to understand what clinical pharmacy services look like in practice for your facility type, we’re glad to have that conversation.
Friendship Pharmacy is a third-generation, family-owned long-term care pharmacy serving assisted living, skilled nursing, memory care, and rehabilitation facilities in the Greater Philadelphia area. Contact us or visit friendshippharmacy.com.
